ストックスクリーナーアプリを入手
0.813
4.09%
-0.0347
前日終値:
$0.8477
開ける：
$0.84
24時間の取引高:
76,381
Relative Volume:
0.21
時価総額：
$7.21M
収益：
$34.07M
当期純損益:
$-20.13M
株価収益率:
-0.0629
EPS:
-12.92
ネットキャッシュフロー:
$-24.90M
1週間 パフォーマンス:
-5.47%
1か月 パフォーマンス:
-16.68%
6か月 パフォーマンス:
-36.48%
1年 パフォーマンス:
-47.21%
1日の値動き範囲:
$0.80
$0.85
1週間の範囲:
$0.80
$0.96
52週間の値動き範囲:
$0.6513
$2.4302
Biofrontera Inc Stock (BFRI) Company Profile
BFRI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
0.813 | 7.21M | 34.07M | -20.13M | -24.90M | -12.92 |
|
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
UTHR
United Therapeutics Corp
|
306.97 | 14.37B | 2.76B | 1.11B | 898.10M | 22.77 |
Biofrontera Inc (BFRI) 最新ニュース
Benchmark maintains Buy rating on Biofrontera stock, target at $7 By Investing.com - Investing.com Australia
Biofrontera Inc. (NASDAQ:BFRI) Q4 2024 Earnings Call Transcript - MSN
Biofrontera Inc. Reports Record Sales and Strategic Advances - MSN
Benchmark maintains Buy rating on Biofrontera stock, target at $7 - Investing.com India
Biofrontera outlines 2025 growth strategies with new FDA approvals and clinical progress - MSN
Biofrontera Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ... By GuruFocus - Investing.com Canada
Biofrontera Inc. Reports Record Revenue Growth in 2024 - TipRanks
Biofrontera Inc. reports Q4 EPS (19c) vs $1.65 last year - TipRanks
Earnings call transcript: Biofrontera Q4 2024 sees revenue growth and strategic shifts - Investing.com India
Biofrontera Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - TradingView
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - GlobeNewswire Inc.
Earnings Scheduled For March 21, 2025 - Benzinga
Biofrontera Inc. (BFRI) reports earnings - Quartz
Biofrontera Inc. SEC 10-K Report - TradingView
Biofrontera Completes Patient Enrollment for Phase 3 Trial of Ameluz in Actinic Keratoses - Marketscreener.com
Biofrontera completes patient enrollment in Phase 3 study of Ameluz - TipRanks
Biofrontera Inc. Announces Completion of Patient Enrollment - GlobeNewswire
Major Milestone: Biofrontera's Skin Cancer Treatment Targets New Body Areas in Phase 3 Trial - StockTitan
3 Reasons to Avoid KIND and 1 Stock to Buy Instead - The Globe and Mail
Biofrontera (BFRI) to Release Earnings on Friday - Defense World
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025 - GlobeNewswire
BIOFRONTERA Earnings Preview: Recent $BFRI Insider Trading, Hedge Fund Activity, and More - Nasdaq
Dermatology Leader Biofrontera Sets Q4 Earnings Date: Key Growth Updates Expected - StockTitan
Biofrontera (BFRI) Projected to Post Earnings on Thursday - Defense World
Biofrontera Inc. (NASDAQ:BFRI) Short Interest Down 25.0% in February - Defense World
Investors Aren't Entirely Convinced By Biofrontera Inc.'s (NASDAQ:BFRI) Revenues - Simply Wall St
When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit? - Yahoo Finance
Biofrontera (NASDAQ:BFRI) Trading Down 3.5% – What’s Next? - Defense World
Constellation Brands: A Fallen Star or a Hidden Value Play? - The Globe and Mail
Head-To-Head Contrast: Indaptus Therapeutics (NASDAQ:INDP) vs. Biofrontera (NASDAQ:BFRI) - Defense World
Biofrontera (NASDAQ:BFRI) vs. Sage Therapeutics (NASDAQ:SAGE) Critical Contrast - Defense World
Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts - ACCESS Newswire
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals - ACCESS Newswire
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024 - ACCESS Newswire
Biofrontera Inc. Announces Preliminary Third Quarter Revenues - ACCESS Newswire
Biofrontera says last patient completed one-year follow-up in Ameluz-PDT study - TipRanks
Biofrontera Inc. Announces Achievement of Key Milestone In - GlobeNewswire
Biofrontera's Ameluz-PDT Skin Cancer Treatment Hits All Phase 3 Endpoints with Strong Results - StockTitan
Photonics IP Update: December 2024 - Laser Focus World
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - The Manila Times
Biofrontera Hits Major Milestone: 100th RhodoLED® XL Lamp Installed as PDT Treatment Demand Surges - StockTitan
Opendoor Technologies Inc (OPEN-Q) QuotePress Release - The Globe and Mail
Financial Contrast: Biofrontera (NASDAQ:BFRI) versus Amicus Therapeutics (NASDAQ:FOLD) - Defense World
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Biofrontera Inc (BFRI:UR): Stock Price, Quote and News - BNN Bloomberg
Biofrontera to Present at Benchmark's Discovery Investor Conference in NYC - StockTitan
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Yahoo Finance
Biofrontera Inc. announced that it expects to receive $4.2 million in funding - Marketscreener.com
Biofrontera Closes a $4.2 Million Senior Secured Convertible Note - citybiz
Biofrontera Inc (BFRI) 財務データ
収益
当期純利益
現金流量
EPS
0.95%
0.05%
大文字化:
|
ボリューム (24 時間):